Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
- 12 Downloads
There is no standard chemotherapy for patients with MBC who progress after exposure to anthracycline and taxane. We conducted this study to assess the outcome of patients who were treated with eribulin.
This was a retrospective study of patients with MBC who were treated with eribulin from December 2016 to March 2018 in Cancer Institute, Chennai.
Twelve patients with MBC previously exposed to both anthracycline and taxane, who received eribulin, were included in this analysis. The overall response rate was 33%. With a median follow-up of 26 months, the median PFS and median OS were 3.5 months and 13.5 months, respectively. Grade 3 neuropathy occurred in 16% of patients.
Eribulin is an option in heavily pre-treated MBC considering the promising long-term outcome. Patients with pre-existing neuropathy should not be considered for eribulin.
KeywordsEribulin Metastatic breast cancer India
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;15(2):CD003372.Google Scholar
- 5.Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256–63.CrossRefGoogle Scholar
- 9.Vahdat LT, Thomas E, Li R, Jassem J, Gomez H, Chung H, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol. 2007;25(18_suppl):1006.Google Scholar
- 10.Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017;161(1):63–72.CrossRefGoogle Scholar
- 11.Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol. 2012;23(5):1164–9.CrossRefGoogle Scholar
- 12.Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013;31(23):2870–8.CrossRefGoogle Scholar
- 14.Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer Oxf Engl. 1990;2019(112):57–65.Google Scholar
- 15.Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601.CrossRefGoogle Scholar
- 16.Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015;154(3):509–20.CrossRefGoogle Scholar
- 19.Srinivasa B, Lalkota BP, Badarke G, Hazarika D, Mohammad N, Sapkota S, et al. Prospective analysis of patients with metastatic breast cancer receiving eribulin mesylate as second or more lines of chemotherapy: an Indian experience. Clin Med Insights Oncol. 2018;1(12):1179554918782475.Google Scholar